Artículos de revistas sobre el tema "Immunocheckpoint"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 38 mejores artículos de revistas para su investigación sobre el tema "Immunocheckpoint".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Rizzo, Mimma, Matteo Santoni y Camillo Porta. "Treatment sequencing strategies in metastatic renal cell carcinoma: A critical interpretation of available data". Journal of Onco-Nephrology 4, n.º 3 (18 de agosto de 2020): 153–64. http://dx.doi.org/10.1177/2399369320943609.
Texto completoSingh, Navdeep, Sandeep Singh Lubana, George Constantinou y Andrea N. Leaf. "Immunocheckpoint Inhibitor- (Nivolumab-) Associated Hypereosinophilia in Non-Small-Cell Lung Carcinoma". Case Reports in Oncological Medicine 2020 (15 de mayo de 2020): 1–5. http://dx.doi.org/10.1155/2020/7492634.
Texto completoBorghaei, Hossein. "Emerging evidence of immunocheckpoint inhibitors in non-small cell lung cancer". Annals of Oncology 28 (octubre de 2017): ix20. http://dx.doi.org/10.1093/annonc/mdx552.
Texto completoCazzato, Gerardo, Eliano Cascardi, Anna Colagrande, Teresa Lettini, Alessandra Filosa, Francesca Arezzo, Carmelo Lupo et al. "T Cell Immunoglobulin and Mucin Domain 3 (TIM-3) in Cutaneous Melanoma: A Narrative Review". Cancers 15, n.º 6 (10 de marzo de 2023): 1697. http://dx.doi.org/10.3390/cancers15061697.
Texto completoSantoni, Matteo, Daniel Y. C. Heng, Gaetano Aurilio, Andrea Iozzelli, Lucilla Servi, Andrea Fabiani, Massimo Giannini et al. "Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma". Current Drug Targets 21, n.º 4 (2 de marzo de 2020): 416–23. http://dx.doi.org/10.2174/1389450120666191017113051.
Texto completoMejías, Claudia y Osmany Guirola. "Pharmacophore model of immunocheckpoint protein PD-L1 by cosolvent molecular dynamics simulations". Journal of Molecular Graphics and Modelling 91 (septiembre de 2019): 105–11. http://dx.doi.org/10.1016/j.jmgm.2019.06.001.
Texto completoEbata, T., T. Shimizu, S. Iizumi, T. Koyama, A. Shimomura, S. Iwasa, S. Kondo et al. "Prognostic factors of patients received immunocheckpoint inhibitors in oncology phase 1 trials". Annals of Oncology 28 (noviembre de 2017): x40. http://dx.doi.org/10.1093/annonc/mdx658.004.
Texto completoSonmez, Ozlem, Ozlem Nuray Sever, Basak Oyan y Osman Gokhan Demir. "Immunotherapy releated cardiomyopathy." Journal of Clinical Oncology 35, n.º 15_suppl (20 de mayo de 2017): e14601-e14601. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e14601.
Texto completoSaigi, Maria, Juan J. Alburquerque-Bejar y Montse Sanchez-Cespedes. "Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front". Oncogene 38, n.º 31 (28 de junio de 2019): 5921–32. http://dx.doi.org/10.1038/s41388-019-0855-x.
Texto completoTakamori, S., T. Komiya y E. Powell. "P75.06 Survival Benefit From Immunocheckpoint Inhibitors in Stage IV Non-Small Cell Lung Cancer Patients With Brain Metastases". Journal of Thoracic Oncology 16, n.º 3 (marzo de 2021): S575—S576. http://dx.doi.org/10.1016/j.jtho.2021.01.1040.
Texto completoZheng, Aixian, Yanlin Du, Yiru Wang, Youshi Zheng, Zhaoyu Ning, Ming Wu, Cuilin Zhang, Da Zhang, Jingfeng Liu y Xiaolong Liu. "CD16/PD-L1 bi-specific aptamer for cancer immunotherapy through recruiting NK cells and acting as immunocheckpoint blockade". Molecular Therapy - Nucleic Acids 27 (marzo de 2022): 998–1009. http://dx.doi.org/10.1016/j.omtn.2022.01.010.
Texto completoTuca, Albert, Rosa Gallego, Ismael Ghanem, Mireia Gil-Raga y Jaime Feliu. "Chemotherapy and Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer". Journal of Clinical Medicine 9, n.º 12 (11 de diciembre de 2020): 4015. http://dx.doi.org/10.3390/jcm9124015.
Texto completoGambini, Donatella, Stefano Ferrero y Elisabetta Kuhn. "Lynch Syndrome: From Carcinogenesis to Prevention Interventions". Cancers 14, n.º 17 (24 de agosto de 2022): 4102. http://dx.doi.org/10.3390/cancers14174102.
Texto completoTessema, Belay, Andreas Boldt, Brigitte König, Melanie Maier y Ulrich Sack. "Flow-Cytometry Intracellular Detection and Quantification of HIV1 p24 Antigen and Immunocheckpoint Molecules in T Cells among HIV/AIDS Patients". HIV/AIDS - Research and Palliative Care Volume 14 (agosto de 2022): 365–79. http://dx.doi.org/10.2147/hiv.s374369.
Texto completoTakamori, S., T. Komiya y E. Powell. "MA15.07 Survival Benefit From Immunocheckpoint Inhibitors in Stage IV Non-small Cell Lung Cancer Patients ≥75 Years Old of Age". Journal of Thoracic Oncology 16, n.º 10 (octubre de 2021): S936. http://dx.doi.org/10.1016/j.jtho.2021.08.193.
Texto completoLiu, Jinhui, Xing Chen, Yi Jiang y Wenjun Cheng. "Development of an immune gene prognostic classifier for survival prediction and respond to immunocheckpoint inhibitor therapy/chemotherapy in endometrial cancer". International Immunopharmacology 86 (septiembre de 2020): 106735. http://dx.doi.org/10.1016/j.intimp.2020.106735.
Texto completoMa, Xiaoting, Yujian Zhang, Shan Wang y Jing Yu. "Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immunocheckpoint inhibitors for non-small cell lung cancer (NSCLC)". Journal of Cancer 12, n.º 2 (2021): 584–94. http://dx.doi.org/10.7150/jca.48105.
Texto completoKakizaki, Masatoshi, Yuichiro Yamamoto, Motoyuki Otsuka, Kouichi Kitamura, Masatoshi Ito, Hideki Derek Kawai, Masamichi Muramatsu, Tatehiro Kagawa y Ai Kotani. "Extracellular vesicles secreted by HBV-infected cells modulate HBV persistence in hydrodynamic HBV transfection mouse model". Journal of Biological Chemistry 295, n.º 35 (10 de julio de 2020): 12449–60. http://dx.doi.org/10.1074/jbc.ra120.014317.
Texto completoZhang, Geng, Yi Xu, Sen Zhang y Huifang Zhou. "The ICOSL Expression Predicts Better Prognosis for Nasopharyngeal Carcinoma via Enhancing Oncoimmunity". BioMed Research International 2020 (9 de enero de 2020): 1–9. http://dx.doi.org/10.1155/2020/9756732.
Texto completoHuang, Wan-Ting, Chee Ho Chew, Amanda Chen, Kang-Yuan Lee, Hsing-Lun Lee, Po-Hao Feng, Jeng-Fong Chiou, Kuan-Chou Lin, Po-Li Wei y Chien-Chung Chen. "Abstract 200: Microtube Array Membrane-Hollow Fiber Assay (MTAM-HFA): A combination of immunocheckpoint blocker (ICBs) and secondary drug anti-cancer drug screening system with significant clinical value propositions for personalized medicine and pre-clinical drug development". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 200. http://dx.doi.org/10.1158/1538-7445.am2022-200.
Texto completoSalabert, Laura, Marine Gross-Goupil, Thibaud Haaser, Jean-Christophe Bernhard, Jean Palussière y Alain Ravaud. "Impact of metastatic local treatment in the strategy of metastatic renal cell carinoma including sterotactic radiotherapy, surgery, and radiofrequency in an expert center." Journal of Clinical Oncology 36, n.º 6_suppl (20 de febrero de 2018): 596. http://dx.doi.org/10.1200/jco.2018.36.6_suppl.596.
Texto completoZhou, Chengzhi, Zhanhong Xie, Yinyin Qin, Laiyu Liu, Hua Zhang, Weineng Feng, Xiaohong Xie et al. "Genomic profiling of pulmonary lymphoepithelioma-like carcinoma (PLELC)." Journal of Clinical Oncology 37, n.º 15_suppl (20 de mayo de 2019): 1572. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.1572.
Texto completoMassari, Francesco, Matteo Santoni, Chiara Ciccarese y Daniele Santini. "The immunocheckpoints in modern oncology: the next 15 years". Expert Opinion on Biological Therapy 15, n.º 7 (10 de junio de 2015): 917–21. http://dx.doi.org/10.1517/14712598.2015.1035251.
Texto completoNdembe, Gloriana, Mirko Marabese, Ilenia Intini, Alessandra Fabbri, Massimo Moro, Mario Occhipinti, Elisa Sottotetti, Giuseppe Lo Russo, Monica Ganzinelli y Massimo Broggini. "Abstract 2380: The effect of metabolic alterations on chemo-immunotherapy response in non-small-cell lung cancer model". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 2380. http://dx.doi.org/10.1158/1538-7445.am2022-2380.
Texto completoLi, Lincheng, Zhaoda Deng, Zhaohui Xiao, Wenbo Zou y Rong Liu. "Analysis of Pyroptosis-Related Signature for Predicting Prognosis and Tumor Immune Microenvironment in Pancreatic Cancer". Frontiers in Oncology 12 (31 de mayo de 2022). http://dx.doi.org/10.3389/fonc.2022.770005.
Texto completoHu, Meng, Weirong Yao y Qinglin Shen. "Advances and challenges of immunocheckpoint inhibitors in the treatment of primary liver cancer". Frontiers in Genetics 13 (30 de septiembre de 2022). http://dx.doi.org/10.3389/fgene.2022.1005658.
Texto completoZhang, Yu, Lifeng Wang, Rutian Li y Baorui Liu. "The emerging development of tumor mutational burden in patients with NSCLC". Future Oncology, 12 de febrero de 2020. http://dx.doi.org/10.2217/fon-2019-0650.
Texto completoBoguszewska-Byczkiewicz, Katarzyna y Agnieszka Kołacińska-Wow. "Liquid biopsy in targeting gene polymorphism related to the response within immunocheckpoint inhibitors therapeutic regimen". Medical Research Journal, 10 de mayo de 2021. http://dx.doi.org/10.5603/mrj.a2021.0022.
Texto completoZhang, Jun, Yu Xia, Xiaomei Zhou, Honghao Yu, Yufang Tan, Yaying Du, Qi Zhang y Yiping Wu. "Current landscape of personalized clinical treatments for triple-negative breast cancer". Frontiers in Pharmacology 13 (16 de septiembre de 2022). http://dx.doi.org/10.3389/fphar.2022.977660.
Texto completoWang, Liguo, Song Han, Changxiang Yan, Yakun Yang, Zhiqiang Li y Zuocheng Yang. "The role of clinical factors and immunocheckpoint molecules in the prognosis of patients with supratentorial extraventricular ependymoma: a single-center retrospective study". Journal of Cancer Research and Clinical Oncology, 2 de enero de 2021. http://dx.doi.org/10.1007/s00432-020-03425-1.
Texto completoChen, Jierong, Lianghe Lu, Chunhua Qu, Gari A, Fangqi Deng, Muyan Cai, Wei Chen, Lie Zheng y Jiewei Chen. "Body mass index, as a novel predictor of hepatocellular carcinoma patients treated with Anti-PD-1 immunotherapy". Frontiers in Medicine 9 (20 de septiembre de 2022). http://dx.doi.org/10.3389/fmed.2022.981001.
Texto completoKawashima, Atsunari, Takayuki Kanazawa, Kumiko Goto, Mitsunobu Matsumoto, Yu Ishizuya, Cong Wang, Yoshiyuki Yamamoto et al. "MP73-02 IMMUNOLOGICAL CLASSIFICATION IN RENAL CELL CARCINOMA BASED ON IMMUNOCHECKPOINT MOLECULES: THE RELATIONSHIP WITH TUMOR AGGRESSIVENESS AND THE PRESENCE OF INTRA-TUMOR DIVERSITY". Journal of Urology 197, n.º 4S (abril de 2017). http://dx.doi.org/10.1016/j.juro.2017.02.3347.
Texto completoTakamori, Shinkichi, Takefumi Komiya y Emily Powell. "Survival benefit from immunocheckpoint inhibitors in stage IV non‐small cell lung cancer patients with brain metastases: A National Cancer Database propensity‐matched analysis". Cancer Medicine, 19 de diciembre de 2020. http://dx.doi.org/10.1002/cam4.3675.
Texto completoMerino, María, Teresa Lozano, Noelia Casares, Hugo Lana, Iñaki F. Troconiz, Timo L. M. ten Hagen, Grazyna Kochan, Pedro Berraondo, Sara Zalba y María J. Garrido. "Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model". Journal of Nanobiotechnology 19, n.º 1 (13 de abril de 2021). http://dx.doi.org/10.1186/s12951-021-00846-z.
Texto completoChiang, Zu-Chian, Shubin Fang, Yang-kun Shen, Dongya Cui, Huanjiao Weng, Dawei Wang, Yuxiang Zhao, Jizhen Lin y Qi Chen. "Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo". Frontiers in Oncology 12 (12 de mayo de 2022). http://dx.doi.org/10.3389/fonc.2022.857927.
Texto completoKawashima, Atsunari, Yoshiyuki Yamamoto, Mototaka Sato, Wataru Nakata, Yoichi Kakuta, Yu Ishizuya, Yuichiro Yamaguchi et al. "FAN score comprising fibrosis-4 index, albumin–bilirubin score and neutrophil–lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumab". Scientific Reports 11, n.º 1 (27 de octubre de 2021). http://dx.doi.org/10.1038/s41598-021-00509-x.
Texto completoRoberta, P., U. Isola, M. Marchetti, M. Giusti, F. Manca y R. Montisci. "P144 PEMBROLIZUMAB–INDUCED MYOCARDITIS". European Heart Journal Supplements 24, Supplement_C (1 de mayo de 2022). http://dx.doi.org/10.1093/eurheartj/suac012.139.
Texto completoAnnibali, Ombretta, Antonella Bianchi, Alba Grifoni, Valeria Tomarchio, Mariantonietta Tafuri, Martina Verri, Giuseppe Avvisati y Anna Crescenzi. "A novel scoring system for TIGIT expression in classic Hodgkin lymphoma". Scientific Reports 11, n.º 1 (29 de marzo de 2021). http://dx.doi.org/10.1038/s41598-021-86655-8.
Texto completo